Mineralys Therapeutics, Inc.
Clinical-stage biopharma developing medicines for aldosterone-driven diseases.
MLYS | US
Overview
Corporate Details
- ISIN(s):
- US6031701013
- LEI:
- Country:
- United States of America
- Address:
- 150 N. RADNOR CHESTER ROAD, 19087 RADNOR
- Website:
- https://mineralystx.com/
- Sector:
- Manufacturing
Description
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The company's primary goal is to improve outcomes for individuals managing hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other related cardio-renal metabolic diseases. Mineralys aims to provide a targeted approach to treatment, addressing the underlying hormonal causes of these conditions to redefine disease management and move beyond traditional trial-and-failure therapeutic strategies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Mineralys Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mineralys Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mineralys Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
